Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661117 | 1.00 | MAPT (0.64) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL22386325 | 0.89 | MAPT (0.67) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL19268087 | 0.88 | TP53 (0.54) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL11827090 | 0.86 | MAPT (0.72) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL31000396 | 0.86 | MAPT (0.72) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL19268075 | 0.85 | GABRP (0.63) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL12683507 | 0.85 | MAPT (0.62) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL19268086 | 0.85 | ALDH1A1 (0.59) | MAPTALDH1A1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL3044265 | 0.84 | KDM4E (0.71) | ALDH1A1TP53SERPINE1GAA | |
| SCHEMBL9790112 | 0.84 | MAPT (0.64) | MAPTALDH1A1LMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595368-B2 | UV/HEVL-filtering contact lenses | ALCON INC. (CH) | 2026-04-07 | — | — | US | disclosed |
| EP-4529621-A1 | UV/HEVL-FILTERING CONTACT LENSES | Alcon Inc. (CH) | 2025-04-02 | — | — | EP | disclosed |
| CN-112189004-B | Process for preparing keto-functionalized aromatic (meth) acrylated products | 赢创运营有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023228055-A1 | UV/HEVL-FILTERING CONTACT LENSES | ALCON INC. (CH) | 2023-11-30 | — | — | WO | disclosed |
| US-20230374306-A1 | UV/HEVL-FILTERING CONTACT LENSES | ALCON INC. (CH) | 2023-11-23 | — | — | US | disclosed |
| US-11505520-B2 | Method for preparing keto-functionalized aromatic (meth)acrylates | EVONIK OPERATIONS GMBH (DE) | 2022-11-22 | — | — | US | disclosed |
| US-20210214297-A1 | METHOD FOR PREPARING KETO-FUNCTIONALIZED AROMATIC (METH)ACRYLATES | EVONIK OPERATIONS GMBH (DE) | 2021-07-15 | — | — | US | disclosed |
| US-20210214297-A1 | METHOD FOR PREPARING KETO-FUNCTIONALIZED AROMATIC (METH)ACRYLATES | EVONIK OPERATIONS GMBH (DE) | 2021-07-15 | — | — | US | disclosed |
| CN-112189004-A | Method for producing keto-functionalized aromatic (meth) acrylates | 赢创运营有限公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-3652139-B1 | METHOD FOR PREPARING KETO-FUNCTIONALIZED AROMATIC (METH)ACRYLATES | EVONIK OPERATIONS GMBH (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3419961-B1 | UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF | ALCON INC (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3652139-A1 | METHOD FOR PREPARING KETO-FUNCTIONALIZED AROMATIC (METH)ACRYLATES | Evonik Operations GmbH (DE) | 2020-05-20 | — | — | EP | disclosed |
| US-10268053-B2 | UV/visible-absorbing vinylic monomers and uses thereof | NOVARTIS AG (CH) | 2019-04-23 | — | — | US | disclosed |
| US-10268053-B2 | UV/visible-absorbing vinylic monomers and uses thereof | NOVARTIS AG (CH) | 2019-04-23 | — | — | US | disclosed |
| EP-3419961-A1 | UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF | Novartis AG (CH) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017145022-A1 | UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF | NOVARTIS AG (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017145022-A1 | UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF | NOVARTIS AG (CH) | 2017-08-31 | — | — | WO | disclosed |
| US-20170242274-A1 | UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF | ALCON INC. (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170242274-A1 | UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF | ALCON INC. (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170242274-A1 | UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF | ALCON INC. (CH) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505520-B2 | Method for preparing keto-functionalized aromatic (meth)acrylates | ALKBH3, ALKBH5, ACR | MAPT 1067/4885ALDH1A1 229/4885LMNA 2868/4885 |
| US-10268053-B2 | UV/visible-absorbing vinylic monomers and uses thereof | VCL, UACA, XRCC6 | MAPT 132/4885ALDH1A1 547/4885LMNA 729/4885 |
| US-12595368-B2 | UV/HEVL-filtering contact lenses | UACA, HSPA4L, RAD54L | MAPT 453/4885ALDH1A1 1073/4885LMNA 2948/4885 |
| US-20210214297-A1 | METHOD FOR PREPARING KETO-FUNCTIONALIZED AROMATIC (METH)ACRYLATES | ALKBH3, ALKBH5, ACR | MAPT 1067/4885ALDH1A1 229/4885LMNA 2868/4885 |
| US-20170242274-A1 | UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF | VCL, UACA, XRCC6 | MAPT 132/4885ALDH1A1 547/4885LMNA 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.